FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)
Cannabis Investing FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario
Cannabis Investing FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
Cannabis Investing FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020
Cannabis Investing FSD Pharma Generates $7.7 Million in Proceeds and 670 Percent Return on Investment through Sale of Interest in Cannara Biotech
Cannabis Investing FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
AMENDED FROM SOURCE - Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
